Invitae (NVTA) is an American medical genetics testing company. The company is leveraging its acquisitions to enhance its offerings. Let’s take a look at Invitae’s latest financial performance, corporate developments, and risk factors. Invitae’s Q2 Financial Results and 2021 Guidance Revenue increased 152% year-over-year to $116.3 million in the second quarter, exceeding consensus estimates of $108.3 million. Invitae posted an adjusted loss per share of $0.85. That marked an improvement from a loss per share of $0.97 in the same quarter last year but missed consensus estimates of a loss per share of $0.65. Invitae ended Q2 with $1.54 billion in cash. (See Invitae stock charts on TipRanks).
https://www.tipranks.com/news/what-can-investors-learn-from-invitaes-newly-added-risk-factors?utm_source=advfn.com&utm_medium=referral
Invitae (NYSE:NVTA)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Invitae Charts.
Invitae (NYSE:NVTA)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Invitae Charts.